These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 7793859)

  • 1. Safety, tolerance, and pharmacokinetics of atevirdine mesylate (U-87201E) in asymptomatic human immunodeficiency virus-infected patients.
    Been-Tiktak AM; Vrehen HM; Schneider MM; van der Feltz M; Branger T; Ward P; Cox SR; Harry JD; Borleffs JC
    Antimicrob Agents Chemother; 1995 Mar; 39(3):602-7. PubMed ID: 7793859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams.
    Morse GD; Reichman RC; Fischl MA; Para M; Leedom J; Powderly W; Demeter LM; Resnick L; Bassiakos Y; Timpone J; Cox S; Batts D
    Antiviral Res; 2000 Jan; 45(1):47-58. PubMed ID: 10774589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections.
    Morse GD; Fischl MA; Shelton MJ; Borin MT; Driver MR; DeRemer M; Lee K; Wajszczuk CP
    Antimicrob Agents Chemother; 1996 Mar; 40(3):767-71. PubMed ID: 8851608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atevirdine (U-87201E) in combination with zidovudine or didanosine.
    Campbell TB; Young RK; Eron JJ; D'Aquila RT; Tarpley WG; Kuritzkes DR
    J Infect Dis; 1993 Aug; 168(2):318-26. PubMed ID: 7687641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absorption, distribution, metabolism, and excretion of atevirdine in the rat.
    Chang M; Sood VK; Wilson GJ; Kloosterman DA; Sanders PE; Schuette MR; Judy RW; Voorman RL; Maio SM; Slatter JG
    Drug Metab Dispos; 1998 Oct; 26(10):1008-18. PubMed ID: 9763407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection. ACTG 199 Study Team.
    Reichman RC; Morse GD; Demeter LM; Resnick L; Bassiakos Y; Fischl M; Para M; Powderly W; Leedom J; Greisberger C
    J Infect Dis; 1995 Feb; 171(2):297-304. PubMed ID: 7531207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerance, and efficacy of atevirdine in asymptomatic human immunodeficiency virus-infected individuals.
    Been-Tiktak AM; Williams I; Vrehen HM; Richens J; Aldam D; van Loon AM; Loveday C; Boucher CA; Ward P; Weller IV; Borleffs JC
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2664-8. PubMed ID: 8913487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate.
    Borin MT; Chambers JH; Carel BJ; Gagnon S; Freimuth WW
    Clin Pharmacol Ther; 1997 May; 61(5):544-53. PubMed ID: 9164416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of atevirdine mesylate (U-87201E) monotherapy in HIV-1-infected patients.
    Demeter LM; Meehan PM; Morse G; Fischl MA; Para M; Powderly W; Leedom J; Holden-Wiltse J; Greisberger C; Wood K; Timpone J; Wathen LK; Nevin T; Resnick L; Batts DH; Reichman RC
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Oct; 19(2):135-44. PubMed ID: 9768622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of fluconazole on the steady-state pharmacokinetics of delavirdine in human immunodeficiency virus-positive patients.
    Borin MT; Cox SR; Herman BD; Carel BJ; Anderson RD; Freimuth WW
    Antimicrob Agents Chemother; 1997 Sep; 41(9):1892-7. PubMed ID: 9303380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery, synthesis, and bioactivity of bis(heteroaryl)piperazines. 1. A novel class of non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Romero DL; Morge RA; Biles C; Berrios-Pena N; May PD; Palmer JR; Johnson PD; Smith HW; Busso M; Tan CK
    J Med Chem; 1994 Apr; 37(7):999-1014. PubMed ID: 7512142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and pharmacokinetics of 5-chloro-2',3'-dideoxy-3'-fluorouridine (935U83) following oral administration of escalating single doses in human immunodeficiency virus-infected adults.
    Riddler SA; Wang LH; Bartlett JA; Savina PM; Packard MV; McMahon DK; Blum MR; Dunn JA; Elkins MM; Mellors JW
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2842-7. PubMed ID: 9124852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers.
    Martin DE; Blum R; Doto J; Galbraith H; Ballow C
    Clin Pharmacokinet; 2007; 46(7):589-98. PubMed ID: 17596104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerance, and preliminary pharmacokinetics of nefazodone after administration of single and multiple oral doses to healthy adult male volunteers: a double-blind, phase I study.
    Barbhaiya RH; Marathe PH; Greene DS; Mayol RF; Shukla UA; Gammans RR; Pittman KA; Robinson D
    J Clin Pharmacol; 1995 Oct; 35(10):974-84. PubMed ID: 8568015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients.
    Borin MT; Chambers JH; Carel BJ; Freimuth WW; Aksentijevich S; Piergies AA
    Antiviral Res; 1997 Jun; 35(1):53-63. PubMed ID: 9224961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetics and safety profile of oral ganciclovir combined with zalcitabine or stavudine in asymptomatic HIV- and CMV-seropositive patients.
    Jung D; AbdelHameed MH; Teitelbaum P; Dorr A; Griffy K
    J Clin Pharmacol; 1999 May; 39(5):505-12. PubMed ID: 10234599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test.
    Cheng CL; Smith DE; Carver PL; Cox SR; Watkins PB; Blake DS; Kauffman CA; Meyer KM; Amidon GL; Stetson PL
    Clin Pharmacol Ther; 1997 May; 61(5):531-43. PubMed ID: 9164415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.
    Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT
    Eur J Clin Pharmacol; 2001; 56(11):805-11. PubMed ID: 11294370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pilot study of the efficacy of atevirdine in the treatment of AIDS dementia complex.
    Brew BJ; Dunbar N; Druett JA; Freund J; Ward P
    AIDS; 1996 Oct; 10(12):1357-60. PubMed ID: 8902064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects.
    Wang LH; Peck RW; Yin Y; Allanson J; Wiggs R; Wire MB
    Antimicrob Agents Chemother; 2003 Apr; 47(4):1334-42. PubMed ID: 12654667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.